Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Treasury Shares: 2021-2025

Historic Treasury Shares for Zevra Therapeutics (ZVRA) over the last 4 years, with Sep 2025 value amounting to $11.0 million.

  • Zevra Therapeutics' Treasury Shares changed negligibly% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $11.0 million for FY2024, which is negligibly% changed negligibly from last year.
  • As of Q4 2024, Zevra Therapeutics' Treasury Shares stood at $1.8 million, which was up 176.12% from $665,739 recorded in Q4 2023.
  • Over the past 5 years, Zevra Therapeutics' Treasury Shares peaked at $1.8 million during Q4 2024, and registered a low of $320,161 during Q4 2021.
  • For the 3-year period, Zevra Therapeutics' Treasury Shares averaged around $1.0 million, with its median value being $909,953 (2022).
  • Data for Zevra Therapeutics' Treasury Shares shows a peak YoY soared of 167.80% (in 2022) over the last 5 years.
  • Zevra Therapeutics' Treasury Shares (Quarterly) stood at $2.8 million in 2021, then skyrocketed by 167.80% to $7.5 million in 2022, then surged by 45.74% to $11.0 million in 2023, then remained steady at $11.0 million in 2024, then remained steady at $11.0 million in 2025.
  • Its last three reported values are $11.0 million in Q3 2025, $11.0 million for Q2 2025, and $11.0 million during Q1 2025.